Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + Chinese herbs refers to the concurrent use or combination therapy of aspirin, a widely used antiplatelet and anti-inflammatory pharmaceutical, with various traditional Chinese herbal medicines. This combination is primarily explored for cardiovascular indications such as atherosclerotic cardiovascular diseases and for addressing aspirin resistance—a phenomenon where patients have reduced response to standard aspirin therapy. Commonly studied Chinese herbs in this context include danshen (Salvia miltiorrhiza), ginkgo biloba, Panax ginseng, Chuanxiong (Rhizoma Chuanxiong), Yan Hu Suo (Corydalis yanhusuo), and others that are believed to promote blood circulation and inhibit platelet aggregation. The mechanism of action involves both pharmacodynamic interactions—such as additive or synergistic inhibition of platelet aggregation—and pharmacokinetic interactions that may alter the metabolism or efficacy of aspirin. While some clinical studies suggest potential benefits in reducing platelet aggregation rates when combining these therapies, evidence quality is variable and safety concerns exist regarding increased bleeding risk due to overlapping antiplatelet effects[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + chinese herbs.